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Recently we reported an association between pediatric obstructive sleep apnea
syndrome (OSAS) and Group A streptococcus (GAS) sub-acute chronic tonsil
colonization. We showed that GAS may contribute to tonsil hyperplasia via a streptolysin
O (SLO)-dependent cysteinyl leukotrienes (CysLTs) production, which can trigger T and
B cell proliferation. In the present study, we characterized the GAS strains isolated
from pediatric OSAS patients in comparison with a panel of age and sex matched
GAS strains unrelated to OSAS, but isolated in the same area and during the same
period ranging from 2009 to 2013. We found that slaA gene, previously reported to be
associated to CysLTs production pathway, was significantly associated to GAS OSAS
strains. Moreover, the most numerous group (32%) of the GAS OSAS strains belonged
to M75 type, and 6 out of 7 of these strains harbored the slaA gene. Multilocus Sequence
Typing (MLST) experiments demonstrated that the clone emm75/ST49/ smeZ, slaA was
associated to OSAS cases. In conclusion, we found an association between slaA gene
and the GAS OSAS strains, and we showed that the clone emm75/ST49 harboring
genes smeZ and slaA was exclusively isolated from patients affected by OSAS, thus
suggesting that this genotype might be associated to the pathogenesis of OSAS,
although further studies are needed to elucidate the possible role of SlaA in tonsil
hypertrophy development.
Keywords: Streptococcus pyogenes, obstructive sleep apnea syndrome (OSAS), slaA gene, Multilocus Sequence
Typing (MLST), molecular epidemiology
INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) has emerged in children, as the primary indication for
surgical removal of adenoids and tonsils (American Thoracic Society, 1996; Marcus et al., 2012;
Ramos et al., 2013). OSAS has been associated with cardiovascular, growth and neurobehavioral
abnormalities, inflammation, and primarily with hypertrophy of the tonsils and adenoids (Goldbart
et al., 2004; Marcus et al., 2012; Zautner, 2012; Kheirandish-Gozal et al., 2013).
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Streptococcus pyogenes is a human pathogen causing a
wide range of diseases (Cunningham, 2000). Although, GAS
is considered the most common single organism associated
with bacterial pharyngo-tonsillitis (Sidell and Shapiro, 2012),
we recently reported an association between pediatric OSAS
and GAS tonsil colonization (Viciani et al., 2016). We showed
that the GAS toxin SLO was involved in cysteinyl leukotrienes
(CysLTs) production, through a SLO-dependent TLR4-mediated,
TRIF and MyD88-dependent p38 MAPK pathway. Cysteinyl
leukotrienes were able to activate primary T and B cell
proliferation in vitro, which is possibly related with the
development of tonsil hypertrophy, and thus with pediatric OSAS
(Viciani et al., 2016).
Following the genome analysis of the M3 GAS strain
MGAS315, the prophage-encoded extracellular phospholipase
A2 (PLA2) SlaA was identified (Beres et al., 2002). SlaA was
reported to cleave palmitic and oleic fatty acids, releasing
arachidonic acid (Nagiec et al., 2004), as in the case of the
cytosolic phospholipase A2 (cPLA2), which also releases the
arachidonic acid from membrane phospholipids favoring its
conversion to leukotrienes and CysLTs by the 5-lipoxygenase
pathway (Funk, 2001). This may lead to final tonsil hypertrophy,
and thus to OSAS (Viciani et al., 2016). SlaA expression is
increased upon contact with cultured epithelial cells and during
growth in human saliva (Banks et al., 2003; Shelburne et al.,
2005); moreover, individuals with serotype M3 GAS infections
produced antibodies against SlaA, indicating that the enzyme
is expressed in vivo during the course of human diseases
(Beres et al., 2002). Of note, the isogenic ∆slaA mutant strain
was severely compromised in its ability to colonize the upper
respiratory tract, leading to the conclusion that SlaA is a key
colonization factor (Sitkiewicz et al., 2006).
In this study, we characterized the GAS strains isolated from
pediatric OSAS patients, investigating the possible association
between a panel of GAS virulence factors (including SlaA) and
OSAS. Moreover, we characterized the genotype of the GAS
strains isolated from OSAS patients, to investigate whether GAS
tonsil colonization could be related to specific clones. To our
knowledge, this is the first study that reports an association
between emm75/ST49 strains harboring smeZ and slaA genes and
pediatric OSAS.
METHODS
Study Design, Patients, and Clinical
Procedures
As recently reported (Viciani et al., 2016), between October 2009
and December 2013, we performed a prospective case-control
study on 120 pediatric patients admitted for tonsillectomy to
the Otorhinolaryngology Unit of the University Hospital of
Siena, which is the only reference unit for this type of surgery
in the Siena province and south-east regional area (Tuscany,
Central Italy). Overall population of Siena province amounts to
269,388 people among which 36,418 are pediatric subjects (0 to
16 years of age). The University Hospital of Siena is a 700-bed
hospital and a total of 900 surgical operations/years are usually
performed at the Otorhinolaryngology Unit, admitting patients
from Siena city, all areas of the province and from Grosseto
and Arezzo provinces. Eligible tonsillectomized patients were
clinically stable children (aged ≤16 years) affected by OSAS
in absence of any signs and symptoms of respiratory diseases,
pharyngitis and/or recurrent pharyngitis. Patients with airway
obstruction and clinical features of OSAS (e.g. intermittent
breathing pauses, heavy snoring, and daytime sleepiness) due to
severe palatine tonsil hypertrophy (Paradise et al., 2002), were
included in the OSAS group. Clinical diagnosis was confirmed
by preoperative evaluation of the patients’ medical histories
based on specific questions to the parents/caregiver and on
physical examinations. Exclusion criteria were: (I) antimicrobial
treatment within 10 days before surgery; (II) coexisting chronic
cardiac, hepatic, renal or pulmonary diseases; (III) acquired
or congenital immunodeficiency; (IV) functional or anatomical
asplenia; (V) systemic corticosteroids therapy; (VI) diabetes;
(VII) craniofacial syndromes; (VIII) neuromuscular disorders,
or (IX) cranial nerve palsies. Among the 120 pediatric subjects
admitted for tonsillectomy at the University Hospital, 40 patients
were affected by OSAS and in 19 of them we isolated one or more
GAS strains, for a total of 22 isolates. In the present study, we
matched them with 59 GAS strains isolated from 59 age and sex
matched non-OSAS subjects recruited in the same period at the
same Hospital of Siena in order to characterize the previously
isolated OSAS GAS strains. All strains were community acquired
because collected within 12 h from admission. Swabs were
performed by different operators immediately before the surgery,
during sedation.
Isolation and Characterization of Bacterial
Strains
As previously reported (Viciani et al., 2016), tonsil swabs and
cores underwent microbiological analysis. Each specimen was
plated on Columbia CNA agar (CNA). Plates were incubated
overnight at 37◦C in a 5% CO2 enriched atmosphere. Overnight
cultures were identified on the basis of macro- and microscopic
morphology and identity was confirmed through specific
biochemical tests, according to standard methods (Murray and
Masur, 2012). Glycerol stocks were made for each bacterial strain
and stored at−80◦C.
Genomic DNA Extraction PCR and
Sequence Analysis
Genomic bacterial DNA employed as template for PCRs
was obtained by boiling the bacterial cells, according to
the CDC protocol (http://www.cdc.gov/streplab/protocol-emm-
type.html). The genomic DNA was immediately used as template
for PCRs or stored at −20◦C for subsequent studies. In order to
amplify the speA, speB, speC, slo, ssa, sil, smeZ, and slaA genes,
primer pairs were designed as described previously (Jing et al.,
2006).
Primers SlaAF: 5′-AGTAATAAATACTATTCTATTAGCT-3′,
and SlaAR: 5′-TTAACATCCTATAGAACCTACTGT-3′ were
used to amplify PCR products and to sequence them using an
Applied Biosystems model 3,730× l DNA Analyzer instrument.
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Co-Culture of GAS Strains with A549
Human Lung Epithelial Cells
A549 cells were cultured on 24-well tissue culture plates with
DMEM containing 25 mM Hepes, 0.1% glutamine, 10% fetal
bovine serum and antibiotics until they reached 80% confluence.
The growth medium was removed, and the cells were washed
with phosphate-buffered saline (PBS). One ml of fresh medium
without antibiotic was added, and the cells were incubated for
2 h. During this time, overnight cultures of GAS test strains
were inoculated into 10 ml of fresh THY medium and cultured
to an A600 = 0.3. The bacteria were collected by centrifugation,
washed once in phosphate-buffered saline, and suspended in 200
microliters of PBS. Hundredmicroliters of bacteria were added to
the A549 cells and incubated for 1 h and 30 min at 37◦C. To test
the time course of induction, one well was harvested immediately
to serve as a 0 h control. After 1 h and 30 min, samples were
trypsinized to collect all the bacteria and centrifuged at 14,000 ×
g for 5min. Pellets were immediately frozen and stored at−80◦C.
Total RNA Isolation, cDNA Synthesis, and
Real-Time qPCR
RNA extraction and RT-PCR experiments were performed
modifying what previously reported (Viciani et al., 2016).
Briefly, total RNA was purified from bacterial pellets co-cultured
with A549 cells and collected at time 0 and after 1 h 30′. We
performed two 30 s disruptions in 1 ml TRIzol (Invitrogen),
using Lysing Matrix B (MP Biomedicals; Solon, OH) in a
Fast Prep FP210 Homogenizer (MP Biomedical) with speed
setting 6.5. Samples were incubated on ice between each
disruption. After 5 min incubation at rt (room temperature),
we centrifuged samples at 14,000 × g for 1 min. Total RNA
in TRIzol was isolated with Direct-zol RNA miniprep (Zymo
research) according to the manufacturer’s recommendations,
treated with 20 U of Turbo DNase (Ambion), and incubated at
37◦C in a thermal bath for 30 min. Samples were then purified
and concentrated with RNA clean & concentrator-5 (Zymo
research). We estimated RNA concentration with the ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA). We designed primers for slaA amplification (forward: 5′-
SlaART_F: TTTAAAGCTAGTTGGCCTGTCC-3′ and reverse:
SlaART_R: 5′- ACAATTAGCACCAATACCGGC-3′) from
S. pyogenesM3, strain GAS315 slaA sequence in GenBank (http://
www.ncbi.nlm.nih.gov/; NC_004587.1; Gene ID: 1257910) using
the software Primer3 (http://simgene.com/Primer3). Previously
validated reference gyrA gene expression (primers: forward:
gyrART_F: 5′-CGACTTGTCTGAACGCCAAA-3′ and reverse
gyrART_R: 5′-TTATCACGTTCCAAACCAGTCAA-3′) was
used as the endogenous control for normalization of the data.
Amplification efficiency was established for each of the genes
from serial dilutions of S. pyogenes genomic DNA. The reactions
were performed in a Light Cycler 480 II (Roche) using the Light
Cycler RNA amplification kit SYBR green I (Roche) according
to the manufacturer’s instructions. Each gene was analyzed in
triplicate and results were evaluated using Light Cycler R© 480 SW
1.5 software (Roche). All reactions amplified a single product
as determined by melting curve analysis. The expression of
slaA gene as compared with the reference gene gyrA expression
was evaluated with the relative quantification method (11CT-
Method). Data were represented as relative amounts of mRNA
normalized to a gyrA control.
Antibiotic Susceptibility Tests
In vitro susceptibility to macrolides and lincosamides was tested
in all 81 isolates. Assays were performed and the results were
interpreted according to Clinical Laboratory Standards Institute
(CLSI) indications (CLSI, 2012). Susceptibility to 14- and 16-
membered ring macrolides (erythromycin, spiramycin) and to
lincosamides (clindamycin) was determined by the Kirby–Bauer
disk diffusion method on Mueller–Hinton agar with 5% sheep
blood plates (Oxoid/Thermo Scientific). In addition to the CLSI
double disk indication, a triple-disk diffusion test was performed
to highlight any possible heterogeneity of inducible resistance, as
described previously (Giovanetti et al., 1999).
emm Typing
emm typing was carried out according to CDC guidelines (http://
www.cdc.gov/streplab/protocol-emm-type.html). Enzymatic
extraction of streptococcal genomic DNA was replaced by
bacterial boiling in distilled water (Tewodros and Kronvall,
2005) and PCR amplification of the emm gene was carried out by
the CDC protocol and PCR product sequencing. Sequenced PCR
products were then compared with the CDC database to retrieve
the emm type.
MLST Analysis
Multilocus Sequence Typing (MLST) analysis was conducted
on all the M75 strains, as previously described (Enright et al.,
2001). This procedure was performed by sequencing seven
housekeeping genes (gki, gtr, murI, mutS, recP, xpt, and yqiL)
according to the S. pyogenes MLST website (http://pubmlst.org/
spyogenes/) sited at the University of Oxford (Jolley and Maiden,
2010). We then compared M75 GAS OSAS strains with M75
GAS strains belonging to three different collections. Collection
one contained a miscellaneous of M75 strains isolated from
patients affected by a number of different pathologies, and was
obtained from the University of Siena, Italy (n = 5); collection
two contained strains isolated from patients affected by throat or
skin infection, and was obtained from the University of Rostock,
Germany (n= 7); collection three contained strains isolated from
patients affected exclusively by pharyngitis, and was obtained
from Baylor College of Medicine Houston, Texas, USA (n= 16).
Statistics
Non-parametric data are presented as median. Data were
analyzed using Z-test (Table 1 sex data; Tables 2–4), non-
parametric Kolmogorov-Smirnov (Table 1 age data), or unpaired
t-test (Figure 1). For all analyses, p < 0.05 was considered
significant. Analyses were done with R software and GraphPad
Prism 7.02 software.
Ethical Declarations
This study was carried out in accordance with the
recommendations of the Ethical Committee of the Azienda
Ospedaliera Universitaria Senese at Siena Hospital with written
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informed consent from all subjects. All subjects and in particular
all the next of kin, caretakers, or guardians on the behalf of the
minors/children participants gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the Ethical Committee of the Azienda Ospedaliera
Universitaria Senese at Siena Hospital.
RESULTS
Presence of slaA Gene Is Prevalent in
Pediatric OSAS Patients
During the characterization of the GAS strains isolated from
pediatric (≤16 years) OSAS patients (Viciani et al., 2016), we
amplified by PCR eight genes encoding virulence factors (Jing
et al., 2006) both in the 22 GAS strains isolated from 19
OSAS patients and in 59 GAS strains isolated from 59 age and
sex matched non-OSAS subjects recruited in the same period
and at the same Hospital of Siena. No significant differences
were noted in the demographics of the matched populations
(Table 1). As shown in Table 2, speB, and slo were detected
in all the GAS isolates analyzed, confirming to be species-
specific, whereas the ssa superantigen was not present in OSAS
or in non-OSAS isolates. Interestingly, slaA gene was found
significantly associated (p = 0.002) with GAS strains isolated
from OSAS patients as compared with GAS strains isolated from
non-OSAS subjects, suggesting a possible role of this virulence
factor in the development of tonsil hypertrophy. None of the
other genes analyzed were found to occur significantly more
frequently in the GAS OSAS group vs. the non-OSAS group. No
significant difference was found in macrolides and lincosamides
TABLE 1 | Demographics of the study population stratified by OSAS
(obstructive sleep apnoea syndrome), and matched with non-OSAS
subjects.
Characteristics OSAS Non-OSAS p-value
No. of patients 19 59 –
Age, years 6 (5–9) (4–11) 6 (5–9) (1–11) 0.77
Sex, male 10 (52.6%) 31 (52.5%) 0.99
Age, median [interquartile range (IQR)] and (minimum age − maximum age). Sex, male
numbers (%). Statistical analysis was performed using a non-parametric Kolmogorov-
Smirnov test on the distribution of age data, and a Z-test on the proportion of cases and
controls for sex data (significance level p = 0.05).
chemo-susceptibility patterns of the isolates from OSAS and
non-OSAS subjects (Table 3).
Presence of slaA Gene Correlates with
M75 Type
The emm type analysis of the GAS strains isolated from OSAS
cases or from non-OSAS subjects showed that most of the isolates
(32%, n = 7) from the GAS OSAS group belonged to M75 type,
whereas only 4 out of 59 (6.8%) of the GAS strains isolated
from non-OSAS subjects belonged to this M type (p = 0.03).
Moreover, no other M type was found to be prevalent in OSAS
or non-OSAS group (Table 4). Interestingly, 6 out of the 7 M75
strains isolated from patients affected by OSAS harbored the
slaA gene (Table S1) which, when sequenced, did not presented
any allelic variation (data not shown). Moreover, when all 6
M75 stains were co-cultured with A549 human epithelial lung
cells, they increased slaA gene expression levels (Figure 1),
showing to harbor host epithelial cell-inducible expression of
slaA gene. We then investigated the presence of slaA gene in
M75 non-OSAS GAS strains isolated from patients affected by
pharyngo-tonsillitis, arthropathy, arthralgia, otitis, skin infection
or superinfection during infectious mononucleosis, belonging to
three different collections of GAS strains isolated in Italy (n =
5), Germany (n = 7) and USA (n = 16). As shown in Table 5,
we obtained four different patterns. Pattern one, harboring genes
TABLE 3 | Macrolides and lincosamides antimicrobial susceptibility of
GAS isolates from OSAS patients and from matched non-OSAS subjects.
Erythro Clinda Spira
GAS OSAS (22)
Susceptible 95.5% (21) 95.5% (21) 95.5% (21)
Intermediate 0.0% 0.0% 0.0%
Resistant 4.5% (1) 4.5% (1) 4.5% (1)
GAS NON-OSAS (59)
Susceptible 93.2% (55) 94.9% (56) 94.9% (56)
Intermediate 0.0% 0.0% 0.0%
Resistant 6.8% (4) 5.1% (3) 5.1% (3)
p 0.71 0.92 0.92
Antibiotics, erythromycin (Erythro), clindamycin (Clinda) and Spiramycin (Spira). Statistical
analysis was performed using a Z-test on the proportion of Susceptible and
Intermediate/Resistant strains (significance level p = 0.05). The percent of isolates is
reported in each cell, along with the corresponding number of isolates in brackets, when
appropriate.
TABLE 2 | Distribution of virulence genes among GAS strains isolated from pediatric OSAS patients and matched GAS strains isolated from non-OSAS
subjects.
speA speB speC smeZ slo ssa sil slaA
GAS OSAS (22) 18.1% (4) 100.0% 45.5% (10) 72.7% (16) 100.0% 0.0% 18.2% (4) 45.5% (10)
GAS non-OSAS (59) 25.4% (15) 100.0% 45.7% (27) 74.6% (44) 100.0% 0.0% 18.6% (11) 13.5% (8)
p 0.49 1 0.98 0.86 1 1 0.96 0.002
Statistical analysis was performed using a Z-test on the proportion of cases and controls (significance level p = 0.05). In each cell the percent of isolates is reported, and in brackets
the corresponding number of isolates when appropriate.
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TABLE 4 | Distribution of emm types among GAS strains isolated from
OSAS patients and from matched non-OSAS subjects.
emm type OSAS n. (%) Non-OSAS n. (%) p-value
emm75 7 (31.8) 4 (6.8) 0.003
emm4 3 (13.6) 4 (6.8) 0.32
emm89 3 (13.6) 10 (16.9) 0.36
emm3 2 (9.1) 1 (1.7) 0.11
emm12 2 (9.1) 8 (13.5) 0.58
emm1 1 (4.5) 7 (11.8) 0.32
emm5 1 (4.5) 4 (6.8) 0.71
emm28 1 (4.5) 3 (5.1) 0.92
emm77 1 (4.5) 1 (1.7) 0.45
emm87 1 (4.5) 1 (1.7) 0.45
emm18 0 (0) 3 (5.1) 0.28
emm6 0 (0) 3 (5.1) 0.28
emm11 0 (0) 2 (3.4) 0.38
emm78 0 (0) 1 (1.7) 0.54
emm29 0 (0) 3 (5.1) 3.28
emm61 0 (0) 2 (3.4) 0.38
emm92 0 (0) 1 (1.7) 0.54
emm9 0 (0) 1 (1.7) 0.54
Total 22 (100.0) 59 (100.0) –
Statistical analysis was performed using a Z-test on the proportion of cases and controls
(significance level p = 0.05).
smeZ and slaA, was prevalent in strains isolated from OSAS
patients in Italy. Pattern two, harboring genes speA, smeZ, and
slaA, was prevalent in strains isolated from patients affected by
different pathologies in Italy. Pattern three, harboring gene smeZ
was prevalent in strains isolated from patients affected by throat
infection in Germany. Pattern four, harboring genes speC and
smeZ was prevalent in strains isolated from patients affected by
pharyngitis in USA. The genes speB and slo were not reported as
they are species-specific. Interestingly, only 4 out of the 28 non-
OSAS GAS strains harbored the slaA gene (Table 5). Therefore,
our results indicated a significant association (p = 0.00018) of
slaA gene with GAS M75 strains isolated from patients affected
by OSAS.
No Correlation was Found between ST and
OSAS Cases
Based on this finding, we decided to perform an MLST analysis
of M75 strains, in order to investigate whether the pattern
harboring slaA gene was due to clonality or to different GAS
strains. Overall, emm75/ST49 type was isolated in Italy and
USA, harboring mostly pattern one, two and four, but also
in one case pattern three (Table 5). On the other hand, clone
emm75/ST150 was prevalent in pattern three in GAS strains
isolated in Germany, harboring neither slaA gene nor speC
gene. However, emm75/ST150 strains were also found harboring
pattern one and pattern three (Table 5). As shown in Table 5,
the MLST analysis revealed that a single clone was responsible
for pattern one in M75 strains isolated from OSAS patients.
In fact, the clone emm75/ST49 harboring slaA and smeZ genes
FIGURE 1 | In vitro expression analysis (real time qRT-PCR), of slaA in
GAS OSAS isolates co-cultured with A549 human epithelial lung cells
and collected at time 0 (t0) or after 1 h 30 min (t1). The quantity of cDNA
for slaA gene was normalized to the quantity of gyrA cDNA in each RNA
sample. The reported values, expressed as fold changes, are the means ±
standard errors from three independently isolated RNA preparations analyzed
in triplicate. *p < 0.05, **p < 0.01, Unpaired t-test.
was associated to OSAS in a period ranging from 2009 to 2011
(Table S1); however, when speA gene was additionally present
(pattern two) no association with OSAS patients was observed.
The Genotype M75/ST49 Harboring slaA
Gene Is Prevalent in OSAS Cases
The characterization of the GAS strains isolated from OSAS
patients showed the significant prevalence of slaA gene in these
isolates as compared with non-OSAS GAS strains isolated in the
same area. Furthermore, 6 out of 7 (85.7%) of the M75 GAS
strains isolated from OSAS patients harbored slaA gene, whereas
the analysis for the presence of this gene in a panel of non-OSAS
M75 strains, isolated in different countries, showed that only 4
out of 28 strains (14.3%) harbored slaA gene. Finally, we showed
that all the M75/ST49 GAS strains colonizing OSAS patients
harbored genes smeZ and slaA, a unique clone circulating in
a period ranging from 2009 to 2011. In fact, interestingly, this
GAS clone was never isolated from non-OSAS patients examined
in the same area and in the same period. Of note, unlike
slaA, the superantigene smeZ was not prevalently associated
with GAS strains isolated from OSAS patients when compared
with GAS strains isolate from non-OSAS subjects (p = 0.86,
Table 2), suggesting that this virulence factor is not particularly
associated to patients affected by OSAS. It has also to be noted
that in M75/ST49 strains the presence of speC gene is negatively
associated to OSAS cases (p= 0.0003).
Taken together these data show the association of GAS clone
emm75/ST49 harboring slaA gene with pediatric patients affected
by OSAS, leading to hypothesize a possible role of the SlaA
protein in the pathogenesis of tonsil hypertrophy, and thus
possibly of obstructive sleep apnea syndrome.
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DISCUSSION
We recently reported an association between pediatric OSAS
and GAS tonsil colonization (Viciani et al., 2016). Based on our
data, we hypothesized a mechanism of pathogenesis where tonsil
hypertrophy, the main risk factor for pediatric OSAS, could be
determined by the proliferative effect that the GAS toxin SLO-
dependent TLR4-mediated, TRIF andMyD88-dependent CysLTs
production has on tonsil T and B cells (Viciani et al., 2016). Here,
we found that slaA gene, previously reported to be involved in
leukotrienes production pathway (Funk, 2001), is significantly
associated to GAS OSAS strains and in particular to the clone
emm75/ST49 harboring smeZ and slaA genes.
In 1997, erythromycin resistance was reported to be in
53% of GAS isolates from Siena; 10 years later the same
resistance phenotype decreased to 16%, these phenotypes being
equally distributed between M (14 and 15 ring member
macrolide-resistant) and MLS (all macrolide, lincosamide, and
streptogramin-resistant) (Cresti et al., 2002; Montagnani et al.,
2009). Although, the genotype emm75/ST49 was one of the most
frequent M-phenotype, carrying mef(A) gene, isolated during
surveys conducted in USA, Spain, Korea and Japan (Green et al.,
2006; Ardanuy et al., 2010; Takahashi et al., 2016), in our study
we found 1 MLS resistant phenotype in all the GAS strains
isolated from the OSAS patients, and 3MLS resistant phenotypes
plus 1 M phenotype in strains isolated from matched non-OSAS
group, no one belonging to M75 type. This very low macrolide
resistance rate was further confirmed by a recent study conducted
in the same area (Olivieri et al., 2015). In a study conducted in
Portugal between 2,000 and 2,005, the genotype emm75/ST150
was significantly associated with pharyngitis (Friaes et al., 2012);
however, interestingly, a mucoid form of a GAS strain M75/ST49
has recently been reported to cause a severe acute otitis media
(Kakuta et al., 2014).
The analysis of the presence of eight virulence factors in the
genome of the GAS OSAS strains showed the species-specificity
of speB and slo as previously reported (Jing et al., 2006; Luca-
Harari et al., 2009). Moreover, the superantigen gene ssa was
not found in our isolates, but was present in 31% of the strains
isolated in a European survey (Luca-Harari et al., 2009), and
in 23% of the isolates in a Chinese study (Jing et al., 2006).
The superantigen gene smeZ was highly represented in our
isolates, as described in other surveys (Jing et al., 2006; Luca-
Harari et al., 2009). In agreement with previous data, speA was
associated with M1 and M3, often involved in severe infections
with high mortality, whereas speC was isolated in several other
types, also associated with high mortality (Schmitz et al., 2003;
Jing et al., 2006; Luca-Harari et al., 2009). The M1 and M3
strains have the gene speA and lack gene speC, suggesting that
the presence of speA affects the acquisition of speC (Schmitz
et al., 2003). In China speA was more prevalent in invasive
than in epipharynx isolates, while speC was significantly over-
represented in epipharynx isolates (Jing et al., 2006). Another
gene related to invasive GAS strains is sil (Hidalgo-Grass et al.,
2004), which we found in 18.2% of OSAS strains similarly to GAS
isolated from China (Jing et al., 2006).
Following the genome analysis of the M3 GAS strain
MGAS315, a prophage-encoded extracellular phospholipase
A2 (PLA2) named SlaA involved in the production of
pro-inflammatory lipid mediators such as leukotrienes was
identified. SlaA had not been present in M3 GAS strains before
1987, when a resurgence of severe invasive disease episodes
occurred (Beres et al., 2002; Ikebe et al., 2002). These data,
together with the reported lack of allelic variation, suggest that
the slaA gene was recently acquired by transduction by a distinct
serotype M3 sub-clone that then spread globally (Nagiec et al.,
2004; Sitkiewicz et al., 2007). It has been reported that slaA was
present, even if uncommonly, in few other serotypes, including
M1, M2, M4, M6, M22, M28, and M75 strains (Nagiec et al.,
2004).
Of note, slaA gene was found in 45.5% of the GAS strains
isolated from OSAS patients, whereas the occurrence rate of this
gene has been reported to be much lower (10.8% in Europe, USA
or Canada and 4.65% in China) (Nagiec et al., 2004; Jing et al.,
2006). On this regard, GAS M75 strains harboring slaA gene,
isolated in 85.7% of the OSAS subjects colonized by GAS, were
reported to be uncommon (Nagiec et al., 2004; Jing et al., 2006;
Kittang et al., 2011) and, when occurring, associated with invasive
strains (Nagiec et al., 2004). Recently, it has been described a high
expression of slaA and of the adjacent gene speK in a skin-tropic
invasive GAS strain, implying an involvement of SlaA in host-
pathogen interactions in the skin and a possible role in enhancing
virulence and fitness in adaption to host niches (Bao et al., 2016).
It has been shown that slaA expression was induced
upon contact with cultured human pharyngeal epithelial cells
(confirmed in this study) and during growth in human saliva
(Banks et al., 2003; Shelburne et al., 2005), and that individuals
with serotype M3 GAS infections seroconvert to SlaA, indicating
that the enzyme is expressed in vivo during the course of
human diseases (Beres et al., 2002). Moreover, interestingly, in
a cynomolgus macaque model of pharyngitis (Sumby et al.,
2005; Virtaneva et al., 2005), the isogenic slaA mutant strain
was severely compromised in its ability to colonize the upper
respiratory tract, leading to the conclusion that SlaA is a
key colonization factor (Sitkiewicz et al., 2007). It has been
demonstrated that SlaA, which is involved in the generation
of pro-inflammatory lipid mediators such as leukotrienes
(Nagiec et al., 2004), is regulated by TLR4 signaling in LPS-
activated macrophages and that the regulation occurs through
TLR4-mediated MyD88- and TRIF-dependent MAPK signaling
pathways (Qi and Shelhamer, 2005). In this study, we observed
a significant association between OSAS cases and GAS strains
genotype emm75/ST49 harboring slaA,. Given that SlaA can
induce CysLTs production and that the latter are involved in
tonsillar T and B cell proliferation, these results could enforce
the recent discovery of a possible role of GAS virulence factors
in tonsil hypertrophy and pediatric OSAS development (Viciani
et al., 2016). However the found correlation does not imply
causation; the multifactorial nature of the disease and the fact
that our data refer to a limited number of cases and are from
a single center in central Italy suggest that the study sample
might not be representative of the whole Italian population.
Ideally our studies should be replicated in a large independent,
multicenter cohort. Moreover, since only a subset (45.5%) of
GAS OSAS strains in our study harbors slaA gene, we cannot
rule out the importance of other risk factors, such as SLO
Frontiers in Microbiology | www.frontiersin.org 7 February 2017 | Volume 8 | Article 294
Viciani et al. SlaA-Strain Prevalence in Pediatric OSAS
toxin; thus slaA gene should be considered as a part of a
combination of factors, which may have a possible role in chronic
diseases.
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